Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on TAK-227 PK in Healthy Adults
NCT05818956Phase 1Completed
- Sponsor
- Takeda
- Start
- May 2023
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ZED1227 in celiac disease (6 arms), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started May 2023; status: completed.
02
Drugs
ZED1227
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05818956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818956.